A new scientific publication involving the synthetic melanocortin agonist NDP-MSH, associated with melanotan I, was released on July 15, 2026. The paper, titled "The Synthetic Melanocortin Agonist NDP-MSH Ameliorates THSD7A-Associated Membranous Nephropathy in an Active Immunization Mouse Model," appeared in The FASEB Journal, the official publication of the Federation of American Societies for Experimental Biology.
The study describes work conducted in an active immunization mouse model related to THSD7A-associated membranous nephropathy. As stated in the publication record, the research focuses on this specific disease model and the compound's role within it. No additional details on methodology, dosing, or outcomes beyond the title are included in this event data.
Melanotan I remains classified as an unapproved research compound. This publication represents an addition to the scientific literature involving NDP-MSH and does not constitute regulatory approval or a change in the compound's current status.
Readers interested in learning more about melanotan I can consult the compound overview for additional context.